Feature | September 06, 2013

Researchers Aim to Use Light — Not Electric Jolts — to Restore Healthy Heartbeats

Johns Hopkins-led research team explores the field of optogenetics

September 6, 2013 — When a beating heart slips into an irregular, life-threatening rhythm, the treatment is well known: deliver a burst of electric current from a pacemaker or defibrillator. But because the electricity itself can cause pain, tissue damage and other serious side-effects, a Johns Hopkins-led research team wants to replace these jolts with a kinder, gentler remedy: light.

In a paper published Aug. 28, 2013, in the online journal Nature Communications, five biomedical engineers from Johns Hopkins and Stony Brook universities described their plan to use biological lab data and an intricate computer model to devise a better way to heal ailing hearts. Other scientists are already using light-sensitive cells to control certain activities in the brain. The Johns Hopkins-Stony Brook researchers say they plan to give this technique a cardiac twist so that doctors in the near future will be able to use low-energy light to solve serious heart problems such as arrhythmia.

“Applying electricity to the heart has its drawbacks,” said the project’s supervisor, Natalia Trayanova, the Murray B. Sachs professor of biomedical engineering at Johns Hopkins. “When we use a defibrillator, it’s like blasting open a door because we don’t have the key. It applies too much force and too little finesse. We want to control this treatment in a more intelligent way. We think it’s possible to use light to reshape the behavior of the heart without blasting it.”

To achieve this, Trayanova’s team is diving into the field of optogenetics, which is only about a decade old. Pioneered by scientists at Stanford, optogenetics refers to the insertion of light-responsive proteins called opsins into cells. When exposed to light, these proteins become tiny portals within the target cells, allowing a stream of ions — an electric charge — to pass through. Early researchers have begun using this tactic to control the bioelectric behavior of certain brain cells, forming a first step toward treating psychiatric disorders with light.

In the Nature Communications paper, the researchers reported that they had successfully tested this same technique on a heart -- one that “beats” inside a computer. Trayanova has spent many years developing highly detailed computer models of the heart that can simulate cardiac behavior from the molecular and cellular levels all the way up to that of the heart as a whole.

As detailed in the journal article, the Johns Hopkins computer model for treating the heart with light incorporates biological data from the Stony Brook lab of Emilia Entcheva, an associate professor of biomedical engineering. The Stony Brook collaborators are working on techniques to make heart tissue light-sensitive by inserting opsins into some cells. They also will test how these cells respond when illuminated.

In Trayanova’s own lab, her team members will use this model to conduct virtual experiments. They will try to determine how to position and control the light-sensitive cells to help the heart maintain a healthy rhythm and pumping activity. They will also try to gauge how much light is needed to activate the healing process. The overall goal is to use the computer model to push the research closer to the day when doctors can begin treating their heart patients with gentle light beams. The researchers say it could happen within a decade.

After the technology is honed through the computer modeling tests, it could be incorporated into light-based pacemakers and defibrillators.

For more information: www.nature.com/ncomms

Related Content

iRhythm Technologies, ZIO continuous cardiac monitoring service, myZIO app, irregular heartbeat symptoms, reporting

Image courtesy of iRhythm Technologies

Technology | ECG Monitoring Services| November 19, 2015
iRhythm Technologies Inc. announced the launch of new patient engagement tools to enhance the diagnosis of cardiac...
wearable Holter monitors, iRhythm, ziopatch, zio patch

iRhythm Technologies Zio Patch was among the first of a new generation of simplified, wearable Holter monitors designed to increase ease of use and patient compliance to increase detection of arrhythmias that may lead to stroke.

Feature | Holter Monitoring Systems| November 16, 2015 | Judy Lenane, RN, MHA
One-third of ischemic strokes are classified as cryptogenic.
Medtronic, Micra TPS, Global Clinical Trial, results

Image courtesy of Medtronic

News | Pacemakers| November 11, 2015
 Medtronic plc announced that the Medtronic Micra Transcatheter Pacing System (TPS) was successfully implanted in...
LivaNova, Platinum, ICD, CRT-D, launch, Europe and Japan

Image courtesy of LivaNova PLC

News | Implantable Cardioverter Defibrillators (ICD)| November 04, 2015
LivaNova PLC, formerly Sorin Group, launched Platinum, a new range of implantable cardiac defibrillators (ICDs) and...
StopAfib.org, atrial fibrillation, AF-related stroke, patient engagement materials

Infographic courtesy of StopAfib.org

News | Stroke| November 03, 2015
In recognition of World Stroke Day, the patient-focused organization StopAfib.org launched a diverse set of materials...
News | Heart Failure| November 02, 2015
Medical device developer Cardionomic Inc. announced that it has received $20 million in Series A financing. Investors...
Boston Scientific, CE Mark, MRI conditional labeling, CRT-Ds, ICDs

X4 CRT-D system image courtesy of Boston Scientific

News | EP Lab| October 30, 2015
Boston Scientific Corp. has received CE Mark on magnetic resonance imaging (MRI) conditional labeling for the current...
Stereotaxis, Niobe remote magnetic navigation system, respiratory compensation, cardiac ablation
Technology | Robotic Systems| October 28, 2015
Stereotaxis Inc. announced the worldwide launch of Respiratory Compensation, a new software feature of the company’s...
Praxbind, Pradaxa reversal agent, FDA approval, emergency situations
Technology | Antiplatelet and Anticoagulation Therapies| October 19, 2015
The U.S. Food and Drug Administration (FDA) granted accelerated approval to Praxbind (idarucizumab) for use in patients...
AtriCure, definitive merger agreement, nContact Inc., atrial fibrillation solutions, cardiac ablation
News | Ablation Systems| October 14, 2015
AtriCure Inc. announced it has entered into a definitive merger agreement under which AtriCure has agreed to acquire...
Overlay Init